Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up.

Concern has been expressed that calcium supplementation, a key intervention for preventing osteoporotic fracture in older women, may increase the risk of atherosclerotic vascular disease. To evaluate the risk further, an examination of complete verified atherosclerotic vascular hospitalization and mortality data from a 5-year randomized, controlled trial (RCT) of calcium carbonate and 4.5 years of posttrial follow-up was undertaken. This study used data from a published 5-year randomized, double-blinded, placebo-controlled trial [Calcium Intake Fracture Outcome Study (CAIFOS)]. The participants were 1460 women aged 75.1 ± 2.7 years at baseline (1998) recruited from the general population and randomized to receive 1200 mg of calcium carbonate daily or an identical placebo. All hospital admission and deaths during the 5-year study and the 4.5-year follow-up were derived from the Western Australian Data Linkage Service (WADLS). Hazard ratios (HRs) for the combined endpoint of atherosclerotic vascular mortality or first hospitalization were calculated using prespecified intention-to-treat and per-protocol models. The intervention group that received calcium supplementation did not have a higher risk of death or first-time hospitalization from atherosclerotic vascular disease in either the 5-year RCT [multivariate-adjusted HR = 0.938, 95% confidence interval (CI) 0.690-1.275] or during the 9.5 years of observational study (multivariate-adjusted HR = 0.919, 95% CI 0.737-1.146). Further analysis suggested that calcium supplementation may reduce the risk of hospitalization and mortality in patients with preexisting atherosclerotic cardiovascular disease. This trial provides compelling evidence that calcium supplementation of 1200 mg daily does not significantly increase the risk of atherosclerotic vascular disease in elderly women.

Quality use of medicines in residential aged care.

BACKGROUND: Older people are more likely to be exposed to polypharmacy. People with dementia, especially those living in residential aged care facilities (RACFs), are at particularly high risk of medication harm. We sought to describe medications prescribed for a sample of people with dementia living in RACFs. METHODS: A total of 351 residents with dementia aged over 65 years were recruited from 36 RACFs in Western Australia. Data on all medications prescribed were collected, including conventional medications, herbal medications, vitamins and minerals. RESULTS: Polypharmacy was identified in 91.2% (average 9.75 medications per person); one-third were prescribed an antipsychotic medication; and 50.4% were found to be taking at least one potentially inappropriate medication. The combination of antipsychotics and antidepressants was the most frequently observed drug-drug interaction, being prescribed to 15.7% of participants. DISCUSSION: People with dementia living in RACFs are commonly exposed to polypharmacy. Prescription of contraindicated medications, antipsychotics, medications with high anticholinergic burden, and combinations of potentially inappropriate medications is also common. There may be substantial scope to improve prescribing for older people with dementia living in RACFs.

Obesity and metabolic syndrome increase the risk of incident depression in older men: the health in men study.

BACKGROUND: Obesity has been associated with increased risk of prevalent depression among young and middle-aged adults, but the association between obesity (and its various measures, including the metabolic syndrome [MetS]) and incident depression has not been examined adequately in the elderly. OBJECTIVES: This study evaluated the association between various measures of obesity and incident depression over a 10-year period in a large cohort of community-based older men. METHODS: The authors recruited 12,216 men aged 65-84 years living in Perth, Australia, between 1996 and 1998, and measured their height, weight, waist and hip circumference, and blood pressure. Participants also completed a questionnaire that included information about the clinical diagnosis and treatment for diabetes, hypertension, and high cholesterol or triglycerides. The authors then used the Western Australian Linked Data System to retrieve information about the following ICD-10 diagnoses between January 1, 1966, and December 31, 2006: depressive episode, recurrent depressive disorder, and dysthymia. RESULTS: The authors excluded 150 men from these analyses because of prior history of depression or missing data. The mean age of our 12,066 participants was 72 +/- 4 years at the time of recruitment, and they were followed up for an average of 8 +/- 2 years. There were 3,623 deaths during follow-up, and 481 men received the diagnosis of depression. The incidence of depression was 5 per 1,000 person-years. Adjusted Cox proportional hazard models showed that men with body mass index (BMI) > or =30 had a 31% (95% confidence interval [CI] = 5%-64%) increase in the risk of depression compared with that of nonobese men (BMI <30). The association between depression and waist circumference > or =102 cm and waist/hip > or =1 did not reach statistical significance. Men with MetS at the time of recruitment had a 137% (95% CI = 60%-251%) increase in the adjusted risk of incident depression. CONCLUSIONS: Our results indicate that obesity and MetS are associated with an increase in the risk of incident depression among older men. If this association is truly causal, reducing the prevalence of obesity and MetS could potentially lead to a decline in the prevalence and incidence of depression in later life.

Use of gastrostomy tubes in older Western Australians: a population-based study of frequency, indications and outcomes.

OBJECTIVE: To determine the number of older Western Australians who had a gastrostomy tube (GT) placement from 1994 to 2004, to describe their characteristics, and to examine outcomes after GT placement, including rehospitalisation for complications and survival. DESIGN AND DATA SOURCES: Secondary analysis of hospital (inpatient) data and linked mortality data from the WA Data Linkage System. MAIN OUTCOME MEASURES: Patient characteristics (age, sex and morbidity profile); numbers of GT closures, replacements and complications within 1 year of GT placement; age- and sex-specific survival outcomes calculated at 7, 30, 60 and 180 days, and 1 and 3 years; and mortality hazard ratios calculated for six conditions of interest, identified using all available diagnosis information on the inpatient record. RESULTS: In Western Australia, 2023 people aged 65 years or older underwent a GT placement for the first time during the period 1994-2004, half of whom had a known history of cerebrovascular disease (50.3%). Rehospitalisation within 1 year for a GT replacement procedure, mechanical complications and incident pneumonitis occurred in 13%, 4% and 9% of patients, respectively. More than half of the patients who underwent a GT placement died within 1 year. Survival outcomes were poorest for patients with motor neurone disease and metastatic cancer. CONCLUSION: To better understand this complex area of health care, questions regarding decision making -- by patients, families, physicians, hospitals and other caring organisations -- about GT placement and maintenance need to be addressed.

Prescribing of psychostimulant medications for attention deficit hyperactivity disorder in children: differences between clinical specialties.

OBJECTIVE: To examine differences in psychostimulant prescribing between paediatricians and child/adolescent psychiatrists for treating children with attention deficit hyperactivity disorder (ADHD) in Western Australia. DESIGN: Using whole-population prescribing data, logistic and linear regressions were used to model the number of children (aged 2-17 years) treated with psychostimulants between August 2003 and December 2004 for ADHD and medication dose prescribed by clinical specialty, controlling for age, sex, body weight, and other medication use. MAIN OUTCOME MEASURES: Mean number of patients treated by specialty; associations between prescriber specialty and patient characteristics; associations between stimulant dose and patient characteristics and prescriber specialty. RESULTS: 54 paediatricians and 23 child/adolescent psychiatrists prescribed stimulant medications for children with ADHD. The mean number of patients treated (per prescriber) was 159.8 (range, 1-1977) for paediatricians and 34.3 (range, 1-166) for psychiatrists. Boys were 32% more likely to be treated with stimulants by paediatricians (P = 0.002). Psychiatrists were 2.9 times (95% CI, 2.4-3.3; P < 0.001) more likely than paediatricians to treat patients with multiple psychotropic medications. When controlled for all other factors, psychiatrists prescribed higher stimulant doses (4.5 mg/day greater; 95% CI, 2.0-7.0 mg/day; P < 0.001) than paediatricians. CONCLUSION: Treatment of children with stimulant medicines for ADHD differed between clinical specialties. Paediatricians treated more patients per prescriber, a greater proportion of boys, and a younger age demographic, but relied less on combined psychotropic pharmacotherapy and prescribed lower stimulant doses than psychiatrists.

Prescribed stimulant use by Western Australians with Attention Deficit Hyperactivity Disorder (ADHD): does amount dispensed exceed the expected authorised use?

OBJECTIVE: To investigate to what extent Western Australian (WA) patients with Attention Deficit Hyperactivity Disorder (ADHD) received prescribed stimulants in excess of their notified dose from WA pharmacies in 2004 (termed 'discrepancy'). DESIGN AND DATA SOURCES: Analysis of administrative data about all people aged two years and older who were prescribed stimulants for the treatment of ADHD in WA, and had at least one stimulant prescription dispensed from a WA pharmacy during the period 1 January to 31 December 2004. OUTCOME MEASURES: Discrepancies were identified using minimum and maximum estimation methods (MinDE, MaxDE). We calculated for both methods the discrepancy prevalence by age and sex and annual surplus of stimulant accrued by age. RESULTS: Of the 15,190 ADHD patients who comprised the study population, 5.4% to 19.0% received stimulants surplus to requirement in 2004, with peak prevalences in 6-8 year-olds (MaxDE 20.1%) and 25-34 year-olds (MaxDE 27.6%; MinDE 10.5%). The amount of stimulant dispensed surplus to requirement was highly skewed, with median annual values that ranged from one to 4.1 standard bottles (100 tablets) of dexamphetamine 5 mg for the MinDE and MaxDE methods, respectively. CONCLUSION: It is difficult to definitively estimate to what extent WA ADHD patients accrued excess stimulant medication using routine administrative data. Improvements to the WA Stimulant Regulatory Guidelines are recommended in the interests of patient safety, public transparency, methodological rigour and encouraging good prescribing practices.

Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed.

OBJECTIVE: To examine treatment with psychostimulant medicines for attention deficit hyperactivity disorder (ADHD) in children (3-17 years) within Western Australia (WA) during 2004. METHODS: Using whole-population-based administrative pharmacy data for 2004, age-specific prevalence of children treated with dexamphetamine and methylphenidate was determined. Treatment with immediate-action and sustained-release stimulants was also examined. Average daily dose (absolute and relative to body weight) of dexamphetamine, methylphenidate and total stimulant medication was also calculated. RESULTS: 9,658 children from 3-17 years (23.5 per 1,000 child population) were treated with stimulant medication for ADHD during 2004. Age-specific prevalence of treatment increased rapidly from three to eight years to peak at 14 years. The male-to-female ratio of stimulant treatment was 4.1. Child prevalence of treatment with dexamphetamine, methylphenidate or combined therapy was 16.4, 8.9 and 1.7 per 1,000 children, respectively. Most children were treated with immediate-action stimulants (16.9 per 1,000 child population), with fewer using sustained-release medicines (4.0 per 1,000 child population). CONCLUSIONS: The prevalence of stimulant medication use for the treatment of ADHD in WA children is 2.4%, with males accounting for the majority of treated patients. Most children were treated with dexamphetamine. Prescribing of methylphenidate, sustained-release stimulants or combined medication therapy was less common. Age-related trends in prescribed daily dose differed for dexamphetamine and methylphenidate.

Stimulant prescribing for the treatment of ADHD in Western Australia: socioeconomic and remoteness differences.

OBJECTIVE: To identify whether the rate and average daily dose of stimulant prescribed for attention deficit hyperactivity disorder (ADHD) in Western Australia differed according to the geographical remoteness and socioeconomic status of the patient. DESIGN AND DATA SOURCES: Secondary analysis of population-based administrative pharmacy data from 2004, stratified by the Accessibility/Remoteness Index of Australia (ARIA+) categories and the Index of Relative Socio-Economic Disadvantage (IRSD) quintiles for WA (2001 Census). OUTCOME MEASURES: Rate ratios of stimulant prescription and mean average daily dose (in dex-equivalents) stratified by age (2-17, 18+ years), sex, ARIA+ category and IRSD quintile. RESULTS: The rate of stimulant prescription was 2.3 to 5.3 times greater in major cities in WA compared with remote and very remote parts of the state. The association between socioeconomic disadvantage and the rate of stimulant prescription was highly variable. Adults with the least socioeconomic disadvantage were significantly more likely to receive stimulants compared with their most disadvantaged counterparts; however, the reverse association was seen with children. The average daily dose of stimulant prescribed did not vary greatly across remoteness or socioeconomic categories. CONCLUSION: Remoteness and socioeconomic disadvantage are significantly associated with rate of stimulant prescription for ADHD in WA, but not associated with average daily dose of stimulant prescribed. Further research is needed to understand why considerable variation exists in the use of prescribed stimulants for ADHD.

In-patient hospital use in the last years of life: a Western Australian population-based study.

OBJECTIVES: To estimate the likelihood and costs of in-patient care in the last three years of life. METHODS: A population-based retrospective cohort study using linked hospital and death records to evaluate in-patient use by Western Australians who died in 2002. RESULTS: Age was unrelated to the likelihood of in-patient admission and inversely related to in-patient costs, after adjustment for sex, cause of death and proximity to death. In-patient costs increased in the final three quarters before death. In the last quarter before death, the predicted average quarterly in-patient cost increased 2.8 fold from quarter two and 3.8 fold from quarter three. CONCLUSIONS: Older decedents were not more likely to be hospitalised than younger decedents in the final three years of life. Moreover, once hospitalised, their in-patient costs were lower. In-patient costs were heavily concentrated in the three last quarters of life. IMPLICATIONS: Remaining lifetime is a significant predictor of in-patient costs. Failure to account for proximity to death will overemphasise the impact of population ageing on health care expenditure, because older people have a higher probability of dying.

High-cost users of hospital beds in Western Australia: a population-based record linkage study.

OBJECTIVE: To describe how high-cost users of inpatient care in Western Australia differ from other users in age, health problems and resource use. DESIGN AND DATA SOURCES: Secondary analysis of hospital data and linked mortality data from the WA Data Linkage System for 2002, with cost data from the National Hospital Cost Data Collection (2001-02 financial year). OUTCOME MEASURES: Comparison of high-cost users and other users of inpatient care in terms of age, health profile (major diagnostic category) and resource use (annualised costs, separations and bed days). RESULTS: Older high-cost users (> or = 65 years) were not more expensive to treat than younger high-cost users (at the patient level), but were costlier as a group overall because of their disproportionate representation (n = 8466; 55.9%). Chronic stable and unstable conditions were a key feature of high-cost users, and included end stage renal disease, angina, depression and secondary malignant neoplasms. High-cost users accounted for 38% of both inpatient costs and inpatient days, and 26% of inpatient separations. CONCLUSION: Ageing of the population is associated with an increase in the proportion of high-cost users of inpatient care. High costs appear to be needs-driven. Constraining high-cost inpatient use requires more focus on preventing the onset and progression of chronic disease, and reducing surgical complications and injuries in vulnerable groups.

Does health assessment improve health outcomes in indigenous people? An RCT with 13 years of follow-up.

OBJECTIVE: To examine the impact of a multi-component health assessment on mortality and morbidity in Kimberley Aboriginal residents during a 13-year follow-up. METHOD: A population-based randomised controlled trial using linked hospital, cancer and death records to evaluate outcomes in 620 intervention and 6,736 control subjects. RESULTS: The intervention group had a higher rate of first-time hospitalisation for any reason (IRR=1.37; 95% CI 1.25-1.50), a higher rate of injury-related hospital episodes (IRR=1.31; 95% CI 1.15-1.48) and a higher notification rate of alcohol-related cancers. There was a smaller difference in the rates of multiple hospitalisations (IRR=1.14; 95% CI 0.75-1.74) and no improvement in overall mortality compared with controls (IRR=1.08; 95% CI 0.91-1.29). CONCLUSIONS: There was no overall mortality benefit despite increased health service contact associated with the intervention. IMPLICATIONS: Although not influencing mortality rates, multi-component health assessment may result in a period of increased health service use in Aboriginal and Torres Strait Islander populations, thus constituting an 'intervention'. However, this should not be confused with systematic and sustained interventions and investment in community development to achieve better health outcomes.

A preliminary case-mix classification system for Home and Community Care Clients in Western Australia.

political and policy settlement further institutionalised surveillance as the basis of the MCHS. The restructured Service has remained constrained by the dominance of health surveillance as the primary program goal even after more varied contracting arrangements replaced CCT. Although recent initiatives indicate signs of hange, narrow surveillancebased guidelines for Victorian MCH Services are not consistent, we argue, with recent early years of life policy which calls for approaches derived from socio-ecological models of health.